Following the FDA’s approval of Retacrit® (epotein alfa-epbx) as the first U.S. biosimilar of Amgen’s Epogen® and Johnson & Johnson’s Procrit® this past May, today Pfizer announced that it has ...
Please provide your email address to receive an email when new articles are posted on . The FDA today approved epoetin alfa-epbx, the first epoetin alfa biosimilar, for the treatment of anemia caused ...
The Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx), a biosimilar of Epogen/Procrit (epoetin alfa), to treat anemia caused by a number of factors – including undergoing ...
FDA LOGO BLUE The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data ...
Credit: Getty Images. Researchers found "no clinically meaningful differences" in efficacy and safety between the biosimilar epoetin alfa-epbx and epoetin alfa. For hemodialysis (HD) patients with ...
The agency has approved Retacrit (epoetin alfa-epbx) by Pfizer’s Hospira, which is a biosimilar to Amgen’s anemia drug, Epogen/Procrit (epoetin alfa). On May 15, 2018, FDA announced that it has ...
* PFIZER INC - RETACRIT IS EXPECTED TO BE AVAILABLE IN U.S. AT A SIGNIFICANT DISCOUNT TO CURRENT WHOLESALER ACQUISITION COST OF EPOGEN AND PROCRIT * PFIZER INC - ENTERED AGREEMENT WITH VIFOR PHARMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results